1.4 Radiation Side Effect Management: Skin & Mucosal Reactions

1.4 Radiation Side Effect Management: Skin & Mucosal Reactions

Acute and late radiation toxicities affecting the skin (radiation dermatitis) and mucous membranes (radiation mucositis) are among the most frequent and clinically significant complications encountered in radiation oncology. Because the epidermis and mucosal linings consist of rapidly renewing epithelial stem cell populations, ionizing radiation interrupts mitotic division and induces cell death faster than tissue regeneration can occur. Effective, evidence-based management of skin and mucosal reactions is essential for preserving patient quality of life, preventing severe secondary infections, maintaining treatment compliance, and preventing unplanned, dosimetrically adverse treatment interruptions.

---

Pathophysiology of Radiation Dermatitis & Mucositis

Radiation dermatitis occurs in up to 95% of patients receiving external beam radiotherapy, particularly those treated for breast, head and neck, anorectal, or vulvar malignancies. The mechanism of damage occurs at both the cellular and molecular levels:

1. Free Radical Generation & DNA Damage

Ionizing radiation interacts with intracellular water molecules through radiolysis, producing highly reactive free radicals, primarily Reactive Oxygen Species (ROS) such as hydroxyl radicals ($\cdot\text{OH}$), superoxide anions ($\text{O}_2^{\cdot-}$), and hydrogen peroxide ($\text{H}_2\text{O}_2$). These ROS induce double-strand DNA breaks and lipid peroxidation within epithelial and microvascular endothelial cells.

2. Stem Cell Depletion in the Epidermal Basal Layer

The epidermis relies on continuous cellular renewal driven by actively dividing stem cells located in the basal layer ($stratum\ basale$). Under normal physiological conditions, basal cells divide and migrate upward through the stratum spinosum and stratum granulosum, eventually cornifying into the protective stratum corneum over a 14-to-28-day cycle. Ionizing radiation causes double-strand DNA damage, mitotic arrest, and apoptosis in basal stem cells. As mature superficial keratinocytes naturally slough off, the depleted basal layer cannot generate replacement cells, resulting in progressive epidermal thinning, denudation, and loss of skin barrier function.

  NORMAL EPIDERMIS                           IRRADIATED EPIDERMIS (20-30 Gy)
  +-----------------------+ Stratum Corneum  +-----------------------+ Sloughing Keratinocytes
  | o   o   o   o   o   o |                  |   .     .     .     . | (Accelerated Loss)
  +-----------------------+ Stratum Spinosum +-----------------------+ Epidermal Thinning
  | ( ) ( ) ( ) ( ) ( )   |                  |  ( )         ( )      | (Loss of Stratum Spinosum)
  +-----------------------+ Basal Layer      +-----------------------+ Stem Cell Depletion
  | [X] [X] [X] [X] [X]   | (Active Mitosis) | [ ]         [ ]       | (Mitotic Arrest / Apoptosis)
  +-----------------------+ Dermis           +-----------------------+ Microvascular Leakage
  | ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ | (Capillaries)    | ~ ~ ~ * ~ ~ ~ * ~ ~ ~ | (Edema & Cytokine Surge)

3. Inflammatory Cytokine Cascades

In response to cellular damage and oxidative stress, irradiated keratinocytes, dermal fibroblasts, and vascular endothelial cells release a cascade of pro-inflammatory cytokines:

• Interleukin-1 (IL-1) & Interleukin-6 (IL-6): Promote microvascular dilation, capillary permeability, local hyperthermia, and recruitment of inflammatory leukocytes into the dermis.
• Tumor Necrosis Factor-alpha (TNF-$\alpha$): Amplifies inflammatory signaling, accelerates keratinocyte apoptosis, causes microvascular endothelial damage, and sensitizes cutaneous nociceptors, causing pain.
• Transforming Growth Factor-beta (TGF-$\beta$): Initiates acute dermal tissue remodeling and plays a central, long-term role in driving chronic microvascular damage, fibroblast proliferation, excessive extracellular matrix deposition, and subcutaneous tissue fibrosis.

4. Pathophysiology of Radiation Mucositis

Like skin, the mucosal lining of the gastrointestinal tract (oral cavity, pharynx, esophagus, rectum) features rapid epithelial turnover. Ionizing radiation damages mucosal basal stem cells, leading to atrophy, submucosal vascular injury, painful mucosal ulceration, and formation of fibrinous pseudomembranes. Pro-inflammatory cytokines (IL-1, TNF-$\alpha$) amplify tissue breakdown, while normal mucosal microbial flora colonize open ulcerations, worsening inflammation and pain.

---

Standardized RTOG & CTCAE v5.0 Toxicity Grading System

The Radiation Therapy Oncology Group (RTOG) and Common Terminology Criteria for Adverse Events (CTCAE v5.0) provide standardized criteria for grading skin toxicity severity based on clinical manifestations, cumulative radiation dose, and biological changes:

---

Evidence-Based Skin Care & Wound Management Protocols

Standardized skin care protocols maintain skin barrier integrity, minimize physical discomfort, and prevent secondary microbial infections:

1. Gentle Skin Cleansing

• Washing Technique: Cleanse treated skin daily using lukewarm water and mild, unfragranced, pH-neutral soaps (e.g., Dove Unscented, Cetaphil, Basis).
• Drying: Gently pat the skin dry with a soft, clean cotton towel. Patients must never rub, scrub, or use abrasive washcloths or loofahs.
• Preserving Alignment Marks: Patients must never scrub or attempt to wash off permanent tattoo marks or temporary ink alignment lines placed for daily treatment setup.

2. Topical Emollients & Moisturizers

• Application Routine: Apply hydrophilic, unfragranced creams or lotions (e.g., Aquaphor, Calendula cream, hyaluronic acid cream, or Biafine) 2 to 3 times daily to soothe dry desquamation and maintain stratum corneum hydration.
• Avoiding Heavy Metallic Ointments: Formulations containing heavy metals—such as zinc oxide, bismuth, or aluminum—must be avoided because high-atomic-number metals cause radiation beam scatter and increase surface dose.

3. Wound Management for Moist Desquamation (Grades 2–3)

• Cleansing & Debridement: Cleanse areas of moist desquamation gently with sterile 0.9% normal saline solution.
• Non-Adherent Barrier Dressings: Apply specialized non-adherent dressings:
  • Silicone Foam Dressings (e.g., Mepilex): Absorb serous exudate, protect exposed dermal nerve endings, and prevent dressing adherence to fragile tissue during removal.
  • Hydrogel Dressings & Polyurethane Films: Maintain a moist wound healing environment, accelerate re-epithelialization, and protect against mechanical friction.
• Infection Monitoring: Inspect skin daily for signs of secondary bacterial (Staphylococcus aureus, Pseudomonas) or fungal (Candida) infection (purulent drainage, foul odor, spreading warmth/erythema). Obtain wound cultures and initiate topical or systemic antimicrobial therapy as prescribed.

4. Environmental & Mechanical Protection

• Clothing: Wear loose, soft, breathable cotton clothing. Avoid tight collars, bra underwires, restrictive waistbands, or synthetic materials that create friction.
• Sun Protection: Protect irradiated skin from direct sunlight during and after therapy (wear UPF 50 physical barrier clothing; avoid chemical sunscreens on compromised skin during treatment).
• Thermal Extremes: Strictly prohibit extreme heat or cold—no ice packs, heating pads, hot water bottles, saunas, or hot tubs on the treatment field.
• Shaving & Adhesives: Avoid shaving the treatment area; if necessary, use an electric razor rather than a manual razor. Avoid applying adhesive tape directly to irradiated skin.

---

Critical Clinical Rule: The Surface Bolus Effect

A fundamental principle of radiation physics and clinical practice governs the timing of topical skin application:

                        [ MEGAVOLTAGE PHOTON BEAM ]
                                     |
               +---------------------+---------------------+
               |                                           |
    CLEAN, DRY SKIN SURFACE                    TOPICAL CREAM PRESENT (BOLUS)
               |                                           |
  Depth of Max Dose (Dmax)                    Depth of Max Dose (Dmax)
  is at 1.5 cm below surface                  Shifts UPWARD to Epidermis
  (Epidermis receives LOW surface dose)       (Epidermis receives MAXIMUM dose!)
               |                                           |
    Normal Skin Sparing                         SEVERE RADIATION DERMATITIS

Physics Mechanism of the Bolus Effect

Megavoltage photon beams (e.g., 6 MV linear accelerator beams) possess a skin-sparing property, meaning electron equilibrium and maximum radiation dose ($D_{max}$) occur at a specific depth below the skin surface (1.5 cm for a 6 MV photon beam). When topical creams, ointments, lotions, petroleum jelly, or thick gels are present on the skin during beam delivery, the topical layer acts as a physical bolus.

Dosimetric Impact & Clinical Risk

The presence of a topical agent shifts the radiation dose buildup region ($D_{max}$) upward toward the skin surface, significantly increasing the superficial dose absorbed by the epidermal basal layer. This unwanted surface dose escalation exacerbates radiation dermatitis, converting mild dry desquamation into severe, premature Grade 2 or 3 moist desquamation.

Absolute Mandatory Clinical Rule

Topical creams, ointments, lotions, or dressings must NEVER be applied within 1 to 2 hours prior to daily radiation fraction delivery. Radiation therapists must inspect the patient's skin prior to treatment setup, ensuring the skin is clean, dry, and completely free of any topical residue before turning on the beam.

---

Oral & Esophageal Mucositis Management Protocols

Radiation-induced mucositis affects patients receiving radiotherapy to the head and neck, thorax (esophagus), or gastrointestinal tract, typically manifesting at cumulative doses of ~20 Gy and reaching peak severity at 40–50 Gy.

1. Bland Oral Hygiene Rinses

• Salt and Soda Solution: Patients should rinse their mouth every 2 to 3 hours with a bland solution composed of 1/2 teaspoon of salt and 1/2 teaspoon of baking soda (sodium bicarbonate) mixed in 1 quart (1 liter) of warm water. This solution neutralizes oral acidity, dissolves tenacious mucus, cleanses ulcerated tissue, and soothes mucosal burning.
• Strict Contraindication: Commercial alcohol-based mouthwashes, lemon-glycerin swabs, acidic juices, spicy foods, extremely hot foods, and rough/crunchy textures are strictly prohibited because alcohol and acids desiccate, burn, and chemically damage fragile mucosal tissue.

2. Compounded Magic Mouthwash Formulations

When oral mucositis causes significant pain, clinicians prescribe compounded oral suspensions known as magic mouthwash. Standard formulations combine equal parts of four key active ingredients:

1. Viscous Lidocaine (2%): Local anesthetic that provides immediate topical analgesia.
2. Diphenhydramine Liquid: Antihistamine that reduces mucosal swelling and inflammation.
3. Aluminum/Magnesium Hydroxide Antacid: Coating agent that helps active medications adhere to mucosal ulcerations.
4. Nystatin or Antifungal Agent: Treats or prevents secondary oral candidiasis (thrush).

Clinical Administration Rule: Patients swish 5 to 10 mL of magic mouthwash in the oral cavity for 1 to 2 minutes and spit (or swallow if treating concomitant esophagitis) 20 to 30 minutes prior to meals to numb the mucosa and enable adequate oral caloric intake.

3. Cryotherapy

Swishing ice chips or ice water in the oral cavity for 30 minutes during short-infusion radiosensitizing chemotherapy (e.g., 5-fluorouracil or melphalan) causes localized mucosal vasoconstriction. This reduces blood flow to oral tissues, limiting chemotherapeutic drug delivery and reducing mucositis severity.

4. Low-Level Laser Therapy (LLLT) / Photobiomodulation (PBMT)

Photobiomodulation uses targeted red or near-infrared laser light (wavelengths 630–670 nm or 780–830 nm) applied to oral mucosa. LLLT stimulates mitochondrial cytochrome c oxidase, boosting ATP production, reducing pro-inflammatory cytokines (TNF-$\alpha$, IL-1), and accelerating mucosal ulcer healing. It is strongly recommended by multinational supportive care guidelines (MASCC/ISOO) for head and neck RT patients.

5. Palifermin (Recombinant Human Keratinocyte Growth Factor / rhKGF)

Palifermin is an intravenous recombinant human keratinocyte growth factor that stimulates epithelial cell proliferation, differentiation, and migration. It is indicated to reduce the incidence, duration, and severity of severe oral mucositis in patients receiving high-dose conditioning therapy prior to hematopoietic stem cell transplantation.

---

Late Radiation Toxicity Considerations

While acute toxicities develop during or immediately after therapy, late radiation toxicities manifest months to years after completing treatment. Late toxicities result from microvascular damage and parenchymal cell depletion, leading to irreversible structural changes:

1. Telangiectasia

• Mechanism: Radiation damages dermal capillary endothelial cells, causing microvascular ectasia and permanent dilation of superficial blood vessels.
• Presentation: Cutaneous lesions appearing as spider-like, purple or bright red dilated capillaries within the irradiated field. While benign, telangiectasia causes cosmetic concern and skin fragility.

2. Subcutaneous Fibrosis

• Mechanism: Driven by persistent, dysregulated Transforming Growth Factor-beta (TGF-$\beta$) signaling, fibroblasts proliferate and secrete excessive extracellular matrix, replacing normal elastic subcutaneous tissue with dense, rigid collagen scar tissue.
• Presentation: Induration, woody firmness, skin tightness, joint stiffness, and restricted range of motion (e.g., cervical stiffness or trismus/lockjaw following head and neck radiotherapy). Managed with physical therapy, pentoxifylline, and vitamin E (vitamin E/pentoxifylline combination therapy).

3. Chronic Mucosal Atrophy & Soft Tissue Necrosis

• Mechanism: Late obliterative endarteritis reduces arterial blood supply, causing chronic tissue hypoxia, loss of mucosal submucosal glands, and loss of epithelial stem cells.
• Presentation: Pale, dry, thin, fragile mucosal tissue that bleeds easily and ulcerates under minimal trauma. Severe cases progress to soft tissue radiation necrosis or osteoradionecrosis (e.g., mandibular osteoradionecrosis following high-dose head and neck radiation >60 Gy), requiring hyperbaric oxygen (HBO) therapy and surgical debridement.